| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2017: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Outline of Final Research Achievements |
A deletion of exons 45-55 in the DMD gene is associated with mild skeletal muscle involvement. Many DMD patients having a mutation within exons 45-55 region could be treated if we were able to skip the entire exon 45-55 region. We established iPS cell lines from T lymphocytes donated from DMD patient with a deletion of exon 46-55, and differentiated iPS cells toward cardiomyocytes. The cardiomyocytes supplemented with phosphorodiamidate morpholono oligomers (PMO) to skip exon 45. The efficiency of exon 45 skipping was occurred with dose-dependent manner. We confirmed a recovery of short length dystrophin proteins. The microarray showed there was no significant difference in the profiling of gene expression between before and after the therapy. The exon skipping therapy using PMO was little affecting other gene expression, and it was possible for exon skipping therapy safely.
|
